Irsenontrine
3 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.
Trials
3
Ongoing
0
Recruiting
0
Completed
3
Sites
67
Countries
8
Endpoints
63
Composite endpoints
0
Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 63 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.
Development
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Most-measured metrics
Top 20 metrics across this asset's endpoints
Normalized metric codes are available for 12 of 63 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.
8
2
2
Trials
Trials for this asset
Every trial for this asset, with the same search, filters, and sort as the Trials tab.
3 of 3
| Asset / Disease area | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT03467152Study To Evaluate the Efficacy, Safety and Tolerability of E2027 (Hereinafter Referred to as Irsenontrine) in Participants With Dementia With Lewy Bodies | Irsenontrine Lewy body dementia | Dementia with Lewy bodies | Ph 2 | Completed | 74 | Apr 2020 | 1 | results |
| NCT04764669A Study of E2027 in Participants With Dementia With Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) With or Without Amyloid Copathology | Irsenontrine Lewy body dementia | Parkinson's disease dementia | Ph 2 | Completed | 14 | Dec 2021 | - | results |
| NCT04023877A Study to Determine the Metabolism and Elimination of [14C]E2027 in Healthy Male Participants | Irsenontrine Lewy body dementia | Age 18-55 | Ph 1 | Completed | 1 | Oct 2019 | - |
Showing 1-3 of 3 trials